Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Trial of Adjuvant Nivolumab or Expectant Observation Following Neoadjuvant Ipilimumab Plus Nivolumab and Surgical Resection of High-Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma

NCT03220009 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT03220009
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03220009 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Trial of Adjuvant Nivolumab or Expectant Observation Following Neoadjuvant Ipilimumab Plus Nivolumab and Surgical Resection of High-Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Withdrawn
Start date
November 3, 2017
Completion date
July 1, 2021
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cervical carcinoma, esophageal carcinoma, mucosal melanoma, mucosal melanoma of the head and neck, oral cavity mucosal melanoma, recurrent melanoma, stage ii vulvar cancer ajcc v7, stage iii vulvar cancer ajcc v7, stage iiia vulvar cancer ajcc v7, stage iiib vulvar cancer ajcc v7, stage iiic vulvar cancer ajcc v7, stage iv oral cavity cancer ajcc v6 and v7, stage iv vulvar cancer ajcc v7, stage iva oral cavity cancer ajcc v6 and v7, stage ivb oral cavity cancer ajcc v6 and v7, stage ivc oral cavity cancer ajcc v6 and v7, vaginal carcinoma